United Therapeutics Says Its Experimental Liver Assist Device Met Primary Goal in Phase 1 Study
MT Newswires Live
Jan 26
United Therapeutics (UTHR) said Monday its subsidiary, Miromatrix's liver assist product, miroliverELAP, met the primary endpoint in a phase 1 study for patients with acute liver failure who were not transplant candidates.
The company said that the open-label study showed that five patients, who were not candidates for a liver transplant, were continuously treated with miroliverELAP for at least 44 hours and survived during treatment.
The drug developer said that no unexpected serious adverse events were reported over a 32-day follow-up, adding that full study results are expected to be published in H2 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.